Psych Pharm Flashcards
medication category for:
first generation- haloperidol
second generation- risperidone
antipsychotics
medication category for:
MAOIs
tricyclics, tetracyclics
SRIs or SRAs
SSRIs, SNRIs
atypical’s or NDRI’s
5HT1a agonist/5HT3 antagonist
SSRI/5HT1a partial agonist
antidepressants
medication category for:
lithium
anti-seizure drug- valproate
anxiolytics-antihistamine, anti-hypertensive, benzodiazepine
mood stabilizers
medication category for:
zolpidem
ramelteon
temazepam
suvorexant
ADHD meds
hypnotics
can neural circuits “learn” over time?
yes
over-stimulated circuits become dysregulated
- circuit activity breaks down resulting in dysfunction
- circuit dysfunciton is seen as symptoms
stimulate receptors
agonist
stimulate with ceiling & occupy receptor (which precludes other NT’s from attaching)
partial agonists
block agonist from receptor
antagonist
blocks agonists at receptor & reduce activity below baseline constitute activity
inverse agonist
psychiatric symptoms related to _______ _______
related to neural circuits
circuit contains ________ and ________
neurotransmitters and receptors
_______ activity drives symptoms
receptor
modulate receptor activity with ______
drugs
excess stimulation of the portions of the CNS that control motor function that are outside of the pyramidal tract
group of syndromes w/ signs of abnormal motor movement result from D2 antagonism (bradykinesia, incoordination, spasms)
extrapyramidal syndrome (EPS)
“late appearing dyskinesias”
a form of EPS
primarily orofacial dyskinesia
D2 receptor blockade
may be permanent
tardive dyskinesia
excess level of 5HT producing akithesia, muscle twitching, hyper-reflexia, penile erection, seizures, coma
serotonin syndrome
excess antagonism of D2 receptor producing muscle rigidity, fever, unstable BP, myoglobinemia
may be fatal
an extreme manifestation
genetically determined hypersensitivity to anesthetic agents resulting in severe hyperthermia, accelerated muscle metabolism, metabolic acidosis
malignant hypertension
syndrome including:
at a minimum, hallucinations, delusions
frequently also disorganized speech and behavior, gross distortions of reality testing
psychosis
drug class for haloperidol
first generation antipsychotic
indications for haloperidol
psychotic symptoms
(defining & associative symptoms)
MoA for haloperidol
D2 antagonist
inhibits alpha1, but not M1, H1
drug class for risperidone
SGA
atypical antipsychotic
indications for risperidone
psychosis (positive & negative symptoms)
mania
MoA for risperidone
5HT and DA antagonist
mild alpha1, alpha2, H1 antagonism
drug class for quetiapine
SGA
atypical antipsychotic
D2 & 5HT antagonist
indications for quetiapine
bipolar disorder
schizophrenia
adjunct in MDD
off-label: GAD, OCD, PTSD
MoA for quetiapine
D2 and 5HT2 antagonism
high affinity for M1 muscarinic receptors
drug class for lurasidone
SGA
atypical antipsychotic
D2, 5HT2, 5HT7 antagonist
5HT1a partial agonist
indications for lurasidone
schizophrenia
bipolar 1 disorder
MoA for lurasidone
D2, 5HT2, 5HT7 antagonist
5HT1 partial agonist
drug class for ziprasidone
SGA
indications for ziprasidone
bipolar disorder
schizophrenia
acute agitation in schizophrenia
MoA for ziprasidone
D2, 5HT2a, 5HT1d antagonist
5HT1a agonist
moderate 5HT and NE reuptake inhibition
what do we want to rule out before treating what looks like depression?
mania
what is the black box warning for all young adults for all antidepressants?
suicide risk
treatment goals:
what is the success rate w/ antidepressants?
60-80%
after starting antidepressants, how long does it take to see improvements in emotions?
2-4 weeks
how long does it take to see the full impact of antidepressants?
6-8 weeks
drug class for phenelzine
monoamine oxidase inhibitor (MAOI)
indications for phenelzine
depression refractory to other Rx, ECT
MoA for phenelzine
inhibition of MAO producing increased NE, DA, 5HT
drug class for nortriptyline
tricyclic antidepressant
indications for nortriptyline
depressive disorders
off-label: chronic pain, anxiety, enuresis, ADHD
MoA for nortriptyline
inhibit SERT, NET
block 5HT2A receptors
drug class for mirtazapine
tetracyclic
alpha2 antagonist
indications for mirtazapine
depression
MoA for mirtazapine
antagonism of alpha2 receptors dishibits 5HT, NE release;
blocks NE negative feedback inhibits of NE, 5HT release
drug class for trazadone
SARIs
5HT2A, 5HT2C antagonist & reuptake inhibitors
indications for trazadone
MDD
insomnia (lower doses)
MoA for trazadone
antagonist of 5HT2A, 5HTC and inhibits reuptake serotonin via SERT, reduces number of 5HT receptors & increasing 5HT flow in neuron